Nancy A. Obuchowski, Ph.D. receives twelfth James L. Mulshine, M.D., International Leadership Award from Prevent Cancer Foundation and American Lung Association
PARA PUBLICACIÓN INMEDIATA
Kyra Meister
703-836-1746
kyra.meister@preventcancer.org
Alexandria Va. – This week, the Prevent Cancer Foundation will award the James L. Mulshine, M.D., International Leadership Award to Nancy A. Obuchowski, Ph.D. during the Foundation’s 21st annual Quantitative Imaging Workshop. The award is given to an individual who has had a profound impact on reducing the toll of lung cancer, COPD and cardiovascular disease.
Nancy A. Obuchowski, Ph.D. is vice chair of the Department of Quantitative Health Sciences in the Lerner Research Institute of the Cleveland Clinic. Her groundbreaking work provides a foundation for the objective evaluation of medical imaging performance for specific biomarker applications, especially for early lung cancer and other major diseases of the chest. Her work on the precision and accuracy of quantitative imaging is proving critical to the routine implementation of artificial intelligence tools in decision support for the clinical management of the lung cancer screening process.
Professor Obuchowski is also a fellow of the American Statistical Association. She has published more than two hundred research articles and book chapters, including the “Handbook for Clinical Trials of Imaging and Image-guided Interventions.”
The Quantitative Imaging Workshop will be held November 14-15, 2024. The event brings together leading experts from around the world for the advancement of quantitative low-dose computerized tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease.
The inaugural Mulshine Leadership Award was presented in 2013. Past award recipients include:
2023 – Professor Matthijs Oudkerk, Co-Principal Investigator of the NELSON randomized screening trial, which successfully demonstrated the mortality benefit of lung cancer screening for Europe.
2022 – Andrea McKee, M.D. and Brady McKee, M.D. (posthumous), for their leadership role in ensuring screening for lung cancer is implemented in all sites of care with the highest quality available.
2021 – Mary M. Pasquinelli, DNP, APRN, FNP-BC, for her contributions to ensuring that access to quality screening is not limited by the zip code in which one lives or the organization in which one is treated.
2020 – Daniel C. Sullivan, M.D., Professor and Vice Chair for Research, Department of Radiology at Duke University Medical Center (retired), for his many contributions to the field, notably the development of the National Lung Screening Trial and implementation of its findings.
2019 – Andrew C. Von Eschenbach, M.D., former director of the National Cancer Institute, for his leadership in the design, funding and activation of the landmark National Lung Screening Trial.
2018 – Sharon Y. Eubanks, J.D., who served as lead prosecutor for the U.S. Department of Justice in the landmark racketeering trial against Big Tobacco, a case which defied predictions and was won by the government.
2017 – The late John Walsh, President and CEO of the COPD Foundation and President and Founder of the Alpha One Foundation, for advocating for the use of CT to detect diseases other than lung cancer.
2016 – Laurie Fenton Ambrose, President, and CEO of the Lung Cancer Alliance, for her efforts to guide successful efforts to gain coverage of lung cancer screening by the Centers for Medicare & Medicaid Services (CMS).
2015 – Claudia Henschke, Ph.D., M.D., Mt. Sinai Hospital (NY), for her pioneering studies of the use of low-dose spiral CT to screen for lung cancer and leadership of a successful effort to mandate that insurance cover the test.
2014 – CVS Caremark Corporation, in recognition of the company’s bold decision to discontinue the sale of tobacco products in their stores.
2013 – Cheryl Healton, DrPH, Founding Dean of the College of Global Public Health at New York University, in recognition of more than 25 years of tireless work in public health, specifically tobacco control.
For more information on this event, visit preventcancer.org/events/quantitative-imaging-workshop.
###
Acerca de la Fundación Prevent Cancer®
La Fundación para Prevenir el Cáncer® is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Through research, education, outreach and advocacy, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated. We are driven by a vision of a world where cancer is preventable, detectable and beatable for all.
La Fundación está avanzando para afrontar el desafío de reducir las muertes por cáncer en 40% para 2035. Para lograrlo, nos comprometemos a invertir $20 millones en tecnologías innovadoras para detectar el cáncer tempranamente y avanzar en la detección de múltiples cánceres, $10 millones para ampliar la detección del cáncer y la vacunación. acceso a comunidades médicamente desatendidas, y $10 millones para educar al público sobre las opciones de detección y vacunación.
Para mayor información por favor visite www.preventcancer.org.